A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced

Brief description of study

The purpose of this study is to learn more about the effects of a drug called AMG 510 in patients with advanced solid tumors with KRAS p.G12C mutation.


Clinical Study Identifier: s19-00359
ClinicalTrials.gov Identifier: NCT03600883
Principal Investigator: Vamsidhar Velcheti
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.